Myeloma and leukaemia trials.

Myeloma and leukaemia trials.

Detalhes bibliográficos
Autor principal:	Peto, R
Formato:	Journal article
Idioma:	English
Publicado em:	1972

Registros relacionados

Myeloma /
por: 455001 Tanner, Jerome E., et al.
Publicado em: (2008)

Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood).
por: Eden, O, et al.
Publicado em: (1991)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, V, et al.
Publicado em: (2020)

Letter: Chemoimmunotherapy of adult acute leukaemia.
por: Peto, R, et al.
Publicado em: (1975)

The adapted Zelen was a feasible design to trial exercise in myeloma survivors
por: Land, J, et al.
Publicado em: (2020)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
por: Edwards, C, et al.
Publicado em: (2007)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
por: Shipman, C, et al.
Publicado em: (2000)

Animal models of multiple myeloma
por: Olechnowicz, SWZ, et al.
Publicado em: (2019)

Myeloma kidney: improving clinical outcomes?
por: Haynes, R, et al.
Publicado em: (2012)

IS THE INCIDENCE OF MULTIPLE-MYELOMA REALLY INCREASING
por: Velez, R, et al.
Publicado em: (1981)

Leukaemia.
por: Kinlen, L
Publicado em: (1994)

Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease
por: Edwards, C, et al.
Publicado em: (2007)

Bisphosphonates--mechanisms of action in multiple myeloma.
por: Shipman, C, et al.
Publicado em: (2000)

Efek Antiproliferatif Pentagamavunon-O Terhadap Sel Myeloma: Atniproliferative Effect of Pentagamanunon-O on Myeloma Cells
por: Perpustakaan UGM, i-lib
Publicado em: (2004)

Myeloma-induced alloreactive T cells arising in Myeloma-infiltrated bones include double-positive CD8(+)CD4(+) T cells: evidence from myeloma-bearing mouse model
por: Freeman, L.M., et al.
Publicado em: (2011)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
por: Shipman, C, et al.
Publicado em: (2000)

Chemotherapy of acute myeloid leukaemia in adults: Medical Research Council.
por: Cuckle, H, et al.
Publicado em: (1979)

Bone marrow adiposity and multiple myeloma
por: Morris, E, et al.
Publicado em: (2018)

Advances in the management of myeloma bone disease.
por: Shipman, C, et al.
Publicado em: (2005)

The pathogenesis of the bone disease of multiple myeloma.
por: Edwards, C, et al.
Publicado em: (2008)

The Bone Marrow Microenvironment in Multiple Myeloma
por: Edwards, C
Publicado em: (2010)

The role of BMP signalling in multiple myeloma
por: Gooding, S
Publicado em: (2018)

Osteoprotegerin and the development of myeloma bone disease
por: Croucher, P, et al.
Publicado em: (2004)

Sulforaphane - A new therapy for mutliple myeloma?
por: Locklin, R, et al.
Publicado em: (2008)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
por: Binet, J, et al.
Publicado em: (1998)

Neonatal leukaemia
por: Roberts, I, et al.
Publicado em: (2018)

Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on Childhood Leukaemia.
por: Chessells, J, et al.
Publicado em: (1994)

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
por: Group, M
Publicado em: (2001)

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
por: Pasquali, S, et al.
Publicado em: (1998)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, N, et al.
Publicado em: (2018)

Engineered nanomedicine for myeloma and bone microenvironment targeting
por: Swami, Archana, et al.
Publicado em: (2015)

Bracken spores and leukaemia.
por: Cook-Mozaffari, P, et al.
Publicado em: (1990)

Host-derived MMP-7 decreases myeloma progression in vivo: An unexpected role for MMP-7 and osteopontin in myeloma pathogenesis
por: Lwin, S, et al.
Publicado em: (2011)

Novel therapeutic targets in myeloma bone disease.
por: Webb, S, et al.
Publicado em: (2014)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
por: Croucher, P, et al.
Publicado em: (2003)

Wnt signaling: bone's defense against myeloma.
por: Edwards, C
Publicado em: (2008)

BTK inhibition in myeloma: targeting the seed and the soil.
por: Edwards, C
Publicado em: (2012)

The role of host microenvironment in the pathogenesis of multiple myeloma
por: Lwin, STS
Publicado em: (2014)

Testing novel therapies for the treatment of multiple myeloma
por: Tosun, C
Publicado em: (2023)

Bisphosphonates and in vivo models of multiple myeloma - Reply
por: Shipman, C, et al.
Publicado em: (2001)